Neurobehavioral consequences of chronic intrauterine opioid exposure in infants and preschool children: a systematic review and meta-analysis

BMC Psychiatry

Colin McCowan³  Dennis J Petrie¹  Kathleen Arbuckle⁴  Alex Baldacchino² 

[1] Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Victoria, Australia;Division of Neuroscience, Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK;Robertson Centre for Biostatistics, Institute of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Boyd Orr Building, Level 11, Glasgow G12 8QQ, UK;Division of Population Health Science, Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK

关键词: Meta-analysis;    Opioids;    Methadone;    Cognition;    Psychomotor;    Neuropsychology;   

Others  :  1123653
DOI  :  10.1186/1471-244X-14-104

 received in 2013-09-26, accepted in 2014-03-26,  发布年份 2014

【 摘 要 】

Background

It is assumed within the accumulated literature that children born of pregnant opioid dependent mothers have impaired neurobehavioral function as a consequence of chronic intrauterine opioid use.

Methods

Quantitative and systematic review of the literature on the consequences of chronic maternal opioid use during pregnancy on neurobehavioral function of children was conducted using the Meta-analysis of Observational Studies in Epidemiology (MOOSE) and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. We searched Cinahl, EMBASE, PsychINFO and MEDLINE between the periods of January 1995 to January 2012.

Results

There were only 5 studies out of the 200 identified that quantitatively reported on neurobehavioral function of children after maternal opioid use during pregnancy. All 5 were case control studies with the number of exposed subjects within the studies ranging from 33–143 and 45–85 for the controls. This meta-analysis showed no significant impairments, at a non-conservative significance level of p < 0.05, for cognitive, psychomotor or observed behavioural outcomes for chronic intra-uterine exposed infants and pre-school children compared to non-exposed infants and children. However, all domains suggested a trend to poor outcomes in infants/children of opioid using mothers. The magnitude of all possible effects was small according to Cohen’s benchmark criteria.

Conclusions

Chronic intra-uterine opioid exposed infants and pre-school children experienced no significant impairment in neurobehavioral outcomes when compared to non-exposed peers, although in all domains there was a trend to poorer outcomes. The findings of this review are limited by the small number of studies analysed, the heterogenous populations and small numbers within the individual studies. Longitudinal studies are needed to determine if any neuropsychological impairments appear after the age of 5 years and to help investigate further the role of environmental risk factors on the effect of ‘core’ phenotypes.

【 授权许可】

   
2014 Baldacchino et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Manchikanti L, Fellows B, Ailinani H, Pampati V: Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 2010, 13(5):401-435.
• [2]Drug misuse statistics in Scotland 2011 [ http://www.isdscotland.org webcite]
• [3]Sameroff A, Seifer R, Zax M, Barocas R: Early indicators of developmental risk: Rochester Longitudinal Study. Schizophr Bull 1987, 13(3):383-394.
• [4]Hanson B, Beschner G, Walters JM, Bovell E: Life with Heroin: Voices from the Inner City. Lexington: D.C. Heath; 1985.
• [5]Konijnenberg C, Melinder A: Prenatal exposure to methadone and buprenorphine: a review of the potential effects on cognitive development. Child Neuropsychol 2011, 17:495-519.
• [6]Hunt RW, Tzioumi D, Collins E, Jeffery HE: Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Hum Dev 2008, 84(1):29-35.
• [7]Hamilton R, McGlone L, MacKinnon JR, Russell HC, Bradnam MS, Mactier H: Ophthalmic, clinical and visual electrophysiological findings in children born to mothers prescribed substitute methadone in pregnancy. Br J Ophthalmol 2010, 94(6):696-700.
• [8]McGlone L, Hamilton R, McCulloch DL, MacKinnon JR, Bradnam M, Mactier H: Visual outcome in infants born to drug-misusing mothers prescribed methadone in pregnancy. Br J Ophthalmol 2014, 98(2):238-245.
• [9]Drug use during pregnancy [ http://www.drugabuse.gov webcite]
• [10]Spiteri Cornish K, Hrabovsky M, Scott NW, Myerscough E, Reddy AR: The short- and long-term effects on the visual system of children following exposure to maternal substance misuse in pregnancy. Am J Ophthalmol 2013, 156(1):190-194.
• [11]NICE: Drug Misuse: Psychosocial Interventions. London: National Institute for Health and Clinical Excellence; 2007.
• [12]Keegan J, Parva M, Finnegan M, Garson A, Belden M: Addiction in pregnancy. J Addict Dis 2010, 29:175-191.
• [13]Simeons S, Matheson C, Inkster K, Ludbrook A, Bond C: The Effectiveness of Treatment for Opiate Dependent Drug Users: An International Systematic Review of the Evidence. Edinburgh: Scottish Executive Drug Misuse Programme; 2002.
• [14]Kimber J, Copeland L, Hickman M, Macleod J, McKenzie J, de Angelis D, Robertson JR: Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 2010, 341:c3172.
• [15]Cornish R, Macleod J, Strang J, Vickerman P, Hickman M: Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK general practice research database. BMJ 2010, 341:c5475.
• [16]Scottish Government: Review of Methadone in Drug Treatment: Prescribing Information and Practice. Edinburgh: Scottish Government; 2007.
• [17]Department of Health (England) and the devolved administrations: Drug Misuse and Dependence: UK Guidelines on Clinical Management. London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive; 2007.
• [18]Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Burls A, Taylor RS: Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007, 11:1-171.
• [19]Farrell M, Ward J, Mattick R, Hall W, Stimson GV, des Jarlais D: Forthnightly review: methadone maintenance in opiate dependence: a review. BMJ 1994, 309(14):1724-1731.
• [20]van Beusekom I, Iguchi M: A review of recent advances in knowledge about methadone maintenance treatment. Santa Monica: RAND; 2001. ISBN 0-8330-3091-4
• [21]Faggiano F, Vigna-Taglianti F, Versino E, Lemma P: Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003, (3):CD002208.
• [22]Pirastu M, Fais R, Messina M, Bini V, Spiga S, Falconieri D, Dianne M: Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies. Drug Alcohol Depend 2006, 83:163-168.
• [23]Darke S, Sims J, McDonald S, Wickes W: Cognitive impairment among methadone maintenance patients. Addiction 2000, 95(5):687-695.
• [24]Ersche KD, Clark L, London M, Robbins TW, Sahakian BJ: Profile of executive and memory function associated with amphetamine and opiate dependence. Neuropsychopharmacology 2006, 31(5):1036-1047.
• [25]Ornstein TJ, Iddon JL, Baldacchino AM, Sahakian BJ, London M, Everitt BJ, Robbins TW: Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology 2000, 23(2):113-126.
• [26]Prosser J, Cohen LJ, Steinfeld M, Eisenberg D, London ED, Galynker II: Neuropsychological functioning in opiate-dependent subjects receiving and following methadone maintenance treatment. Drug Alcohol Depend 2006, 84:240-247.
• [27]Lombardo WK, Lombardo B, Goldstein A: Cognitive functioning under moderate and low dosage methadone maintenance. Int J Addict 1976, 11(3):389-401.
• [28]Rotheram-Fuller E, Shoptaw S, Berman SM, London ED: Impaired performance in a test of decision-making by opiate-dependent tobacco smokers. Drug Alcohol Depend 2004, 73:79-86.
• [29]King R, Best D: Cognitive functioning and cognitive style among drug users in maintenance substitution treatment. Drug Educ Prev Polic 2011, 18(2):132-139.
• [30]Baldacchino A, Balfour D, Passetti F, Humphris G, Matthews K: The neuropsychological consequences of chronic opioid use: a quantitative review and meta-analysis. Neur BioBeh Rev 2012, 36:2056-2068.
• [31]Kandall SR, Albin S, Lowinson J, Berle B, Eidelman AI, Gartner LM: Differential effects of maternal heroin and methadone use on birthweight. Pediatrics 1976, 58(5):681-685.
• [32]Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O’Grady KE, Selby P, Martin PR, Fischer G: Neonatal abstinence syndrome after methadone or buprenorphine exposure. Obstet Gynecol Surv 2011, 66:191-193.
• [33]Cleary BJ, Eogan M, O’Connell MP, Fahey T, Gallagher PJ, Clarke T, White MJ, McDermott C, O’Sullivan A, Carmody D, Gleeson J, Murphy DJ: Methadone and perinatal outcomes: a prospective cohort study. Addiction 2012, 107(8):1482-1492.
• [34]Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M: Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev 2013, 12:CD006318.
• [35]de Cubas MM, Field T: Children of methadone-dependent women: developmental outcomes. Am J Orthopsych 1993, 63(2):266-276.
• [36]Hans SL: Developmental consequences of prenatal exposure to methadone. Ann N Y Acad Sci 1989, 562:195-207.
• [37]Rosen TS, Johnson HL: Long-term effects of prenatal methadone maintenance. In Current Research on the Consequences of Maternal Drug Abuse NIDA Research Monograph. 59th edition. Edited by Pinkert TM. Rockville, Maryland: National Institute on Drug Abuse; 1985:73-83.
• [38]Bauman PS, Levine SA: The development of children of drug addicts. Int J Addict 1986, 21(8):849-863.
• [39]Konijnenberg C, Melinder A: Neurodevelopmental investigation of the mirror neurone system in children of women receiving opioid maintenance therapy during pregnancy. Addiction 2013, 108(1):154-160.
• [40]Salo S, Kivistö K, Korja R, Biringen Z, Tupola S, Kahila H, Kivitie-Kallio S: Emotional availability, parental self-efficacy beliefs, and Child Devin caregiver-child relationships with buprenorphine-exposed 3-year-olds. Parent Sci Pract 2009, 9:244-259.
• [41]Soepatmi S: Developmental outcomes of children of mothers dependent on heroin or heroin/methadone during pregnancy. Acta Paediatr 1994, 83:36-39.
• [42]Whitham JN, Spurrier NJ, Sawyer MG, Baghurst PA, Taplin JE, White JM, Gordon AL: The effects of prenatal exposure to buprenorphine or methadone on infant visual evoked potentials. Neurotoxicol Teratol 2010, 32:280-288.
• [43]Hutchings DE: Methadone and heroin during pregnancy: a review of behavioral effects in human and animal offspring. Neurobehav Toxicol Teratol 1982, 4:429-434.
• [44]Wolf FM: Meta-Analysis: Quantitative Methods for Research Synthesis, Volume 59. London: Sage Publications; 1986.
• [45]Borenstein M, Hedges L, Higgins JPT, Rothstein HR: Introduction to Meta-Analysis. Chichester, Sussex: Wiley; 2009.
• [46]Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283(15):2008-2012.
• [47]Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.
• [48]Britannica: Child Development: process and definition. 2013. Accessed http://www.britannica.com/EBchecked/topic/111044/child-development webcite
• [49]Organization WH: The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva: WHO; 1993.
• [50]American Psychiatric Association: Diagnostic and statistical manual of mental disorders fourth edition. 1994. Accessed: http://www.dsm.psychiatryonline.org/book.aspx?bookid=556 webcite (June 2013)
• [51]Cooper H, Hodges LV: The Handbook of Research Synthesis. New York: Russel Sage Foundation; 1984.
• [52]Cohen J: Statistical Power Analysis for the Behavioural Sciences. Abington: Massachusetts Lawrence Erlbaum Associates; 1988.
• [53]Hunter JE, Schmidt FL: Methods of Meta-Analysis. London: Sage Publications; 1990.
• [54]Cohen J: A power primer. Psychol Bull 1992, 112(1):155-159.
• [55]Hedges LV, Olkin I: Statistical Methods for Meta-Analysis. Cambridge: Academic Press; 1985.
• [56]Sternberg RJ, Grigorenko EL: Genetics of childhood disorders: I. Genetics and intelligence. J Am Acad Child Adolesc Psychiatry 1999, 38:486-488.
• [57]Lezak MD, Howieson DB, Loring DW: Neuropsychological Assessment. 4th edition. Oxford: Oxford University Press; 2004.
• [58]Anderson LW, Krathwohl DR, Airasian PW, Cruikshank KA, Mayer RE, Pintrich PR, Raths J, Wittrock MC: A Taxonomy for Learning, Teaching, and Assessing: A Revision of Bloom’s Taxonomy of Educational Objectives. New York: Addison Wesley Longman; 2001.
• [59]Demakis GJ: Meta-analysis in neuropsychology: basic approaches, findings, and applications. Clin Neuropsychol 2006, 20(1):10-26.
• [60]Strauss E, Sherman EMS, Spreen O: A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. Oxford: Oxford University Press; 2006.
• [61]Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J: Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006, 11:193-206.
• [62]Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560.
• [63]Hedges LV, Verea JL: Fixed-and random effects models in meta-analysis. Psychol Methods 1998, 3:486-504.
• [64]Quinhana SM, Minami T: Guidelines for meta-analyses of J Couns Psycholresearch. J Couns Psychol 2006, 34:839-877.
• [65]Orwin RG: A fail safe N for effect size. J Stat Educ 1983, 8:157-159.
• [66]Borenstein M, Hedges L, Higgins J, Rothstein H: Comprehensive Meta Analysis. 2nd edition. Englewood, New Jersey: Biostat; 2005.
• [67]National Collaborating Centre for Methods and Tools: Quality Assessment Tool for Quantitative Studies. Hamilton, ON: McMaster University; 2008. (Updated 13 April, 2010). Retrieved from http://www.nccmt.ca/registry/view/eng/14.html webcite
• [68]Grattan M, Hans S: Motor behaviour in children exposed prenatally to drugs. Phys Occup Ther Pediatr 1996, 16(1/2):89-109.
• [69]Walhovd KB, Moe V, Slinning K, Due-Tonnessen P, Bjornerud A, Dale AM, van der Kouwe A, Quinn BT, Kosofsky B, Greve D, Fischl B: Volumetric cerebral characteristics of children exposed to opiates and other substances in utero. Neuroimage 2007, 36:1331-1344.
• [70]Steinhausen HC, Blattmann B, Pfund F: Developmental outcome in children with intrauterine exposure to substances. Eur Addict Res 2007, 13:94-9100.
• [71]Moe V: Foster-placed and adopted children exposed in utero to opiates and other substances: prediction and outcome at four and a half years. J Dev Behav Pediatr 2002, 23(5):330-339.
• [72]Ornoy A: The impact of intrauterine exposure versus postnatal environment in neurodevelopmental toxicity: long-term neurobehavioral studies in children at risk for developmental disorders. Toxicol Lett 2003, 140–141:171-181.
• [73]Bunikowski R, Grimmer I, Heiser A, Metze B, Schafer A, Obladen M: Neurodevelopmental outcome after prenatal exposure to opiates. Eur J Pediatr 1998, 157(9):724-730.
• [74]Hans SL, Jeremy RJ: Postneonatal mental and motor development of infants exposed in utero to opioid drugs. Inf Mental Health J 2001, 22(3):300-315.
• [75]Zakzanis KK: Statistics to tell the truth, the whole truth, and nothing but the truth Formulae, illustrative numerical examples, and heuristic interpretation of effect size analyses for neuropsychological researchers. Arch Clin Neuropsych 2001, 16(7):653-667.
• [76]Verdejo-Garcia A, Perez-Garcia M: Profile of executive deficits in cocaine and heroin polysubstance users: common and differential effects on separate executive components. Psychopharmacology (Berl) 2007, 190(4):517-530.
• [77]Emory EK, Israelian MK: Behavioral Profiles Related to Stress Reactivity and Ethnic Variation. Proceedings of Advancing Research on Developmental Plasticity. Bethesda, Maryland: National Institutes of Health; 1998.
• [78]Fihrer I, McMahon CA, Taylor AJ: The impact of postnatal and concurrent maternal depression on child behaviour during early school years. J Affect Disord 2009, 119:116-123.
• [79]NICHD: Chronicity of maternal depressive symptoms, maternal sensitivity, and child functioning at 36 months. NICHD early child care research network. Dev Psychol 1999, 35(5):1297-1310.
• [80]Petterson SM, Albers AB: Effects of poverty and maternal depression on early child development. Child Dev 2001, 72(6):1794-1813.
• [81]Grace SL, Evindar A, Stewart DE: The effect of postpartum depression on child cognitive development and behavior: a review and critical analysis of the literature. Arch Womens Ment Health 2003, 6:263-274.
• [82]Tong S, Baghurst P, McMichael A: Birthweight and cognitive development during childhood. J Paediatr Child Health 2006, 42(3):98-103.
• [83]Dunlop AJ, Panjari M, O’Sullivan H, Henschke P, Love V, Ritter A: Clinical Guidelines for the Use of Buprenorphine in Pregnancy. Fitzroy, Victoria: Turning Point Alcohol and Drug Centre; 2003.
• [84]Johnson RE, Jones HE, Fischer G: Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003, 70:87-8101.
• [85]Bernstein IM, Mongeon JA, Badger GJ, Solomon L, Heil SH, Higgins ST: Maternal smoking and its association with birth weight. Obstet Gynecol 2005, 106(5 Pt 1):986-991.
• [86]Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O’Grady KE, Selby P, Martin PR, Fischer G: Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010, 363:2320-2331.